InflaRx to Participate in Major Investor Conferences
In a noteworthy announcement, InflaRx N.V. (Nasdaq: IFRX), a leading biopharmaceutical company specializing in anti-inflammatory therapeutics, is gearing up for participation in two significant investor conferences in September. This engagement comes as the company continues to push boundaries in treating inflammatory diseases through innovative solutions.
Details of the Upcoming Conferences
Cantor Global Healthcare Conference 2025
The first event of interest is the Cantor Global Healthcare Conference, which is set to take place from September 3 to 5, 2025, in New York. InflaRx will hold a fireside chat on September 4 at 9:10 AM ET, providing an opportunity to delve into its strategic initiatives and product developments.
In addition to the fireside chat, the company plans to engage in one-on-one investor meetings on the same day. This engagement will allow attendees to gain deeper insights into InflaRx's growth trajectory and future plans.
H.C. Wainwright 27th Annual Global Investment Conference
Following the Cantor conference, InflaRx will also participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025. The company’s presentation is scheduled for September 9 at 3:30 PM ET and will showcase the latest advancements in its research and product development.
Similar to the previous event, InflaRx will conduct one-on-one investor meetings on September 9, allowing for direct interaction between the company leaders and investors. This direct dialogue works to strengthen relationships and foster collaboration opportunities.
About InflaRx N.V.
InflaRx is at the forefront of biopharmaceutical innovation, focusing on anti-inflammatory therapeutics by targeting the complement system. One of its most notable developments is vilobelimab, an advanced anti-C5a monoclonal antibody that selectively targets the complement activation factor C5a. This innovative treatment has demonstrated promising clinical efficacy and safety across various studies.
The company is also actively developing INF904, a small molecule that aims to inhibit C5a-induced signaling. This focus on cutting-edge therapeutic solutions positions InflaRx to play a significant role in addressing a spectrum of inflammatory conditions.
Founded in 2007, InflaRx operates from bases in Jena and Munich, Germany, along with a subsidiary in Ann Arbor, Michigan, USA. This global presence underlines the company’s commitment to comprehensive research and development in the field of biopharmaceuticals, which is essential for reaching broader markets.
Contact Information
InflaRx N.V.
Vice President, Head of Investor Relations
Email: IR@inflarx.de
MC Services AG
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu
Contact in Europe: +49 89-210 2280
Contact in the U.S.: +1-339-832-0752
Frequently Asked Questions
What does InflaRx focus on?
InflaRx specializes in developing anti-inflammatory therapeutics, primarily targeting the complement system.
What are the dates of the upcoming investor conferences?
The Cantor Global Healthcare Conference is from September 3 to 5, and the H.C. Wainwright Conference is from September 8 to 10, 2025.
Where will the conferences take place?
Both conferences are being held in New York.
How can investors engage with InflaRx at the conferences?
Investors can participate in one-on-one meetings scheduled during both conferences.
What is vilobelimab?
Vilobelimab is InflaRx's lead product, a monoclonal antibody that targets C5a, demonstrating significant potential in treating various inflammatory conditions.
